Navigation Links
Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
Date:3/31/2009

mers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                Media
    info@peregrinei
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
2. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
6. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
7. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
8. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
9. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... in the journal PNAS (Proceedings of the National ... day and sleep deprivation have a significant effect on ... at the best time of day to test for ... administering medicines effectively. , Researchers from the University of ... the links between sleep deprivation, body clock disruption and ...
(Date:7/10/2014)... Wash. The lithium-ion batteries that power our laptops ... longer on a single charge with the help of ... porous material to replace the graphite traditionally used in ... than 10 times the energy storage capacity of graphite. ... battery electrode was published today in Nature Communications ...
(Date:7/10/2014)... study by researchers at the University of Illinois ... mechanisms governing the interplay of spin and heat ... of ultrafast spintronic devices for data storage and ... as well as spin-angular momentum. In a typical ... is no spin current," explained David Cahill, a ...
(Date:1/15/2014)... , "The interface is the device," Nobel laureate ... properties to be found at the junctures where ... world of nanotechnology, the interfaces between layers of ... in such high-tech favorites as spintronics, high-temperature superconductors, ...
Breaking Biology Technology:Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3University of Illinois study advances limits for ultrafast nano-devices 2A deeper look at interfaces 2
... - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - ... the fiscal 2009 third quarter and nine-month period ended ... for its fiscal year 2009 now ending on February, ... period ended February 28, 2009 in the range of ...
... regular improvements in information technology, says Slava Rotkin, but ... Take the laptop, for example. Its components, especially its ... while the instrument,s power and capacity increase. But heat ... melt and the laptop hardware to fail. , Indeed, ...
... Approval for SIMPONI , ... Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: ... granted approval of SIMPONI (TM) (golimumab),as a once-monthly, ... active rheumatoid arthritis (RA), active psoriatic arthritis (PsA),and ...
Cached Biology Technology:Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5New 'near-field' radiation therapy promises relief for overheating laptops 2New 'near-field' radiation therapy promises relief for overheating laptops 3Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8
(Date:7/11/2014)... news release is available in German . ... is a method that uses the refraction of X-rays ... The images produced with this method are often of ... scientists in the team of Prof. Franz Pfeiffer are ... imaging and therapy including X-ray phase-contrast imaging. One ...
(Date:7/11/2014)... members to reduce aggression and gain access to scarce ... activities shows a certain pattern across the day. The ... Biology Letters . , Grooming between individuals in a ... To be groomed has hygienic benefits and is stress ... provide access to infants, mating opportunities and high quality ...
(Date:7/11/2014)... transplantation of mesenchymal stem cells can stimulate neurogenesis in ... Alzheimer,s disease (AD) and improve tissue and function injury ... reported on the therapeutic effect of adipose-derived stem cells ... effect on oxidative injury and neurogenesis in the brain ... School of Life Sciences, Tsinghua University, China transplanted ADSCs ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... state-of-the-art electron microscopy techniques, a team led by researchers ... described the precise arrangement of chemoreceptorsthe receptors that sense ... have found that this specific architecture is the same ... that this is a stable, universal structure that has ...
... EAST LANSING, Mich. - It,s been cultivated for at least ... every continent except Antarctica. Now the humble potato has had ... important vegetable worldwide," said Robin Buell, an MSU associate professor ... released the first draft sequence of the potato genome. "This ...
... chemicals to observe how basic cellular activities differ between healthy ... too slow or too toxic to perform on live cells. ... Faculty of 1000 Biology and leading authority in chemistry and ... chemical reaction to make live cancer cells light up quickly ...
Cached Biology News:Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 3Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 4MSU scientist helps map potato genome, hope to improve crop yield 2